Almirall, S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LBTSF research report →
About the company
Almirall, S. A. is a biopharmaceutical company specializing in the research, development, manufacturing, and commercialization of dermatology-focused pharmaceuticals.
- CEO
- Carlos Gallardo Piqué
- IPO
- 2012
- Employees
- 2,026
- HQ
- Barcelona, ES
Price Chart
- Market Cap
- $3.34B
- P/E
- 46.63
- P/S
- 1.81
- P/B
- 1.62
- EV/EBITDA
- 5.36
- Div Yield
- 1.33%
- Gross Margin
- 52.35%
- Op Margin
- 6.47%
- Net Margin
- 3.82%
- ROE
- 3.53%
- ROIC
- 2.76%
- Revenue
- $1.11B · 12.37%
- Net Income
- $46.18M · 355.14%
- EPS
- $0.21 · 384.99%
- Op Income
- $67.69M
- FCF YoY
- 20316.67%
- 52W High
- $15.47
- 52W Low
- $9.01
- 50D MA
- $14.96
- 200D MA
- $12.80
- Beta
- 0.17
- Avg Volume
- 173
Get TickerSpark's AI analysis on LBTSF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our LBTSF coverage
Recent articles, reports, and earnings notes.
No research on LBTSF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LBTSF report →Similar companies
Peers in the same neighborhood.